Elixinol Wellness Limited

Strategic Acquisition and Capital Raising - Investor Presentation | 3 October 2024

Elixinol Wellness Ltd. (”EXL”) has entered into a binding agreement to acquire 100% of the business assets from the entities ("Acquisition") that together form The Healthy Chef business ("Healthy Chef").


ACQUISITION PURCHASE PRICE

  • The aggregate total Purchase Price will be between $3.1 million - $5.5 million, with the final amount determined on1st March 2028(Final Settlement). ThePurchase Price willbe calculated on a sliding scale with a minimum of $3.1 million and a maximum of $5.5 million if the grossrevenue generated by Healthy Chef in Financial Year 2027 is over $10 million.
  • ThePurchase Price comprises:

a) Ordinary Shares in EXLto the valueof $400,000 (Consideration Shares), calculated at 30-day VWAP on 10 September, subject to shareholder approval and under a 12-month escrow period

b) The remainder of the Purchase Price to be paid incash according tothe agreed Deferred Payment Schedule

DEFERRED PAYMENT SCHEDULE

  • EXL agrees to pay Healthy Chef:

a) $600,000 in upfront cash at the closing of the proposed Transaction (Completion)

b) $450,000 in cash on the 1st annual anniversary of Completion

c) $600,000 in cash on the 2nd annual anniversary of Completion

d) The remainder of the Purchase Price to be paid in cash on the Final Settlement date

FUNDING

  • Funding of the Acquisition will consist of:

a) A single-tranche placement of $1.1 millionand Share PurchasePlan (SPP) to raise up to $0.5 million

b) Canaccord Genuity is acting as Lead Manager to the Equity Raising, see Pg. 25 for details

c) Deferred consideration is anticipated to be funded from operational cashflow

Click here for the full ASX Release

This article includes content from Elixinol Wellness Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

The Conversation (0)
Sort by

FDA APPROVES LUMAKRAS® IN COMBINATION WITH VECTIBIX® FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER

Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS ® (sotorasib) in combination with Vectibix ® (panitumumab) for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. Approval is based on the pivotal Phase 3 CodeBreaK 300 study, which demonstrated that LUMAKRAS plus Vectibix is the first and only targeted treatment combination for chemorefractory KRAS G12C-mutated mCRC to show superior progression-free survival (PFS) compared to the investigated standard-of-care (SOC). 1*

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

FDA APPROVES LUMAKRAS® IN COMBINATION WITH VECTIBIX® FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER

Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS ® (sotorasib) in combination with Vectibix ® (panitumumab) for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. Approval is based on the pivotal Phase 3 CodeBreaK 300 study, which demonstrated that LUMAKRAS plus Vectibix is the first and only targeted treatment combination for chemorefractory KRAS G12C-mutated mCRC to show superior progression-free survival (PFS) compared to the investigated standard-of-care (SOC). 1*

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Cizzle Brands Corporation Teams up with Hockey Influencer, Coach Chippy, to launch Tropical Flow, a Special Edition Coach Chippy Inspired Flavour of CWENCH Hydration

Cizzle Brands Corporation Teams up with Hockey Influencer, Coach Chippy, to launch Tropical Flow, a Special Edition Coach Chippy Inspired Flavour of CWENCH Hydration

With a combined social media following of more than one million users, Coach Chippy is a leading influencer in youth hockey. Through his Tropical Flow flavour of CWENCH Hydration, which will be available for purchase at Pro Hockey Life, Source for Sports, Sports Excellence and other leading retailers, Coach Chippy will be creating greater visibility for CWENCH Hydration in a key demographic for the brand.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Sirona Biochem Showcases TFC-1326 in Stonegate Healthcare's Landmark Report

Sirona Biochem Showcases TFC-1326 in Stonegate Healthcare's Landmark Report

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is excited to announce that its cutting-edge anti-aging compound, TFC-1326, has been highlighted in Stonegate Healthcare Partners' latest research report. The publication, titled "Sirona Biochem's TFC-1326 Clinical Data Versus Retinoid Clinical Data," provides an extensive evaluation of TFC-1326's clinical trial performance, setting it apart from traditional retinoid treatments.

The report outlines the remarkable benefits of TFC-1326, including:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Biotech therapy capsule containing DNA strand surrounded by cells.

Top 4 Canadian Biotech Stocks (Updated January 2025)

Biotech is a dynamic industry that is driving scientific advancements and innovation in healthcare. In Canada, the biotech industry is home to companies pursuing cutting-edge therapies and medical technologies.

According to Grandview Research, the global biotech market is expected to grow at a compound annual growth rate of 13.96 percent between 2024 and 2030 to reach a value of US$3.08 trillion.

Here, the Investing News Network profiles the five best-performing Canadian biotech stocks based on their year-on-year gains.

Keep reading...Show less

Latest Press Releases

Related News

×